An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes

A Multi-center, Prospective Observational Study to Investigate the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes

This study investigated the effectiveness of pravastatin on renal function in Korean dyslipidemic patients with Type 2 diabetes.

This survey study investigated the effect of routine initiation single dose of pravastatin (10 mg, 20 mg, or 40 mg) on renal function in Korean dyslipidemic patients with Type 2 diabetes. The study also examined the effect of pravastatin on lipid profiles, glucose metabolism, and safety.

Inclusion Criteria:

• Participants with Type 2 diabetes (currently using an antidiabetic drug or satisfying diagnostic criteria of diabetes as defined by American Diabetes Association)
• Participants with dyslipidemia (currently using an antidyslipidemic drug or satisfying the Health Insurance Review & Assessment Service insurance coverage treatment criteria*) for whom drug treatment with pravastatin is confirmed
• Participants determined to be eligible as subjects at the discretion of the investigator
• Participants who voluntarily provided written consent using the Informed Consent Form on Use of Information

Exclusion Criteria:

• Participants who had administered pravastatin prior to study participation
• Participants with hypersensitivity to the investigational product or its history
• Participants with an active liver disease or persistent elevation of transaminase with an unknown cause
• Pregnant woman or women with childbearing potential, breastfeeding mothers
• Children
• Participants with severe hepatic or renal insufficiency
• Participants with myopathy
• Participants with cholestasis
• Participants with hypercholesterolemia due to hyperalphalipoproteinemia accompanied by HDL cholesterol elevation
• Participants with a genetic problem such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption